Journal of Lipid and Atherosclerosis最新文献

Cardioprotective Effects of Adiponectin-Stimulated Autophagy.

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2024-11-07 DOI: 10.12997/jla.2025.14.1.40

Eddie Tam, Mireille Ouimet, Gary Sweeney

{"title":"Cardioprotective Effects of Adiponectin-Stimulated Autophagy.","authors":"Eddie Tam, Mireille Ouimet, Gary Sweeney","doi":"10.12997/jla.2025.14.1.40","DOIUrl":"10.12997/jla.2025.14.1.40","url":null,"abstract":"Cardiovascular diseases (CVDs), including heart failure, pose a significant economic and health burden worldwide. Current treatment strategies for heart failure are greatly limited, in that they mainly mitigate symptoms or delay further progression. In contrast, therapies aimed at proactively preventing the onset of heart failure could greatly improve outcomes. Adiponectin is an adipocyte-derived hormone that confers an array of cardioprotective effects. It exerts anti-inflammatory effects, improves metabolic function, mitigates endothelial cell dysfunction, and reduce cardiomyocyte cell death. Furthermore, it has gained increasing attention for its ability to activate autophagy, a conserved cellular pathway that facilitates the degradation and recycling of cell components. The disruption of autophagy has been linked to CVDs including heart failure. Additionally, growing evidence also points to specific forms of autophagy, namely mitophagy and lipophagy, as crucial adaptive responses in protection against CVDs. The protective effects of adiponectin, autophagy, mitophagy, and lipophagy against CVDs along with potential therapeutic implications will be discussed.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"14 1","pages":"40-53"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143254758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association Between Lipoprotein (a) Levels and Coronary Artery Disease (CAD) Among Patients With or Without CAD Family History.

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2024-12-26 DOI: 10.12997/jla.2025.14.1.120

Hayato Tada, Nobuko Kojima, Kan Yamagami, Yasuaki Takeji, Kenji Sakata, Soichiro Usui, Masa-Aki Kawashiri, Masayuki Takamura

{"title":"Association Between Lipoprotein (a) Levels and Coronary Artery Disease (CAD) Among Patients With or Without CAD Family History.","authors":"Hayato Tada, Nobuko Kojima, Kan Yamagami, Yasuaki Takeji, Kenji Sakata, Soichiro Usui, Masa-Aki Kawashiri, Masayuki Takamura","doi":"10.12997/jla.2025.14.1.120","DOIUrl":"10.12997/jla.2025.14.1.120","url":null,"abstract":"Objective: Lipoprotein (a) (Lp[a]), which is a highly heritable trait, is associated with coronary artery disease (CAD). However, the insight into whether the association between Lp(a) and CAD differs according to the family history of CAD remains unclear.Methods: We investigated clinical data of 4,512 participants who underwent serum Lp(a) level measurement at Kanazawa University Hospital between 2008 and 2016. The association between Lp(a) and CAD according to CAD family history was investigated through logistic regression analyses.Results: CAD family history and Lp(a) levels were significantly associated with CAD development (odds ratio [OR], 1.32; 95% confidence interval [CI], 1.12-1.52; p<0.001 and OR, 1.13; 95% CI, 1.03-1.23; p<0.001 per 10 mg/dL, respectively). In patients without CAD family history, those with Lp(a) levels ≥30 mg/dL had higher CAD risk than those with Lp(a) levels <30 mg/dL (reference) (OR, 1.33; 95% CI, 1.05-1.61; p<0.001). In patients with CAD family history, those who had Lp(a) levels <30 and ≥30 mg/dL were both highly at risk for CAD (OR, 1.24; 95% CI, 1.04-1.44; p<0.001 and OR, 1.68; 95% CI, 1.34-2.02; p<0.001, respectively). Adding CAD family history and Lp(a) information to other conventional risk factors enhanced CAD risk discrimination (C-statistics: 0.744 [0.704-0.784] to 0.768 [0.730-0.806], and 0.791 [0.751-0.831], respectively; p<0.05 for both).Conclusion: Lp(a) level was associated with CAD development regardless of CAD family history status.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"14 1","pages":"120-127"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791416/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chylomicron Characteristics Are Associated With Microsomal Triglyceride Transfer Protein in an Animal Model of Diet-Induced Dysbiosis.

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2024-11-14 DOI: 10.12997/jla.2025.14.1.106

Carolina Olano, Gregorio Fariña, Morena Wiszniewski, Jimena Medel, Celina Morales, Silvia Friedman, Vanesa Macri, Magalí Barchuk, Gabriela Berg, Laura Schreier, Valeria Zago

{"title":"Chylomicron Characteristics Are Associated With Microsomal Triglyceride Transfer Protein in an Animal Model of Diet-Induced Dysbiosis.","authors":"Carolina Olano, Gregorio Fariña, Morena Wiszniewski, Jimena Medel, Celina Morales, Silvia Friedman, Vanesa Macri, Magalí Barchuk, Gabriela Berg, Laura Schreier, Valeria Zago","doi":"10.12997/jla.2025.14.1.106","DOIUrl":"10.12997/jla.2025.14.1.106","url":null,"abstract":"Objective: Intestinal remnant chylomicrons (CMs) are involved in cardiovascular residual risk and the atherogenic process. Microsomal triglyceride transfer protein (MTTP) catalyzes the assembly of lipids to apolipoprotein B48, generating CMs. Dysbiosis could alter this behavior. This study investigated the chemical composition of CMs and their associations with intestinal MTTP and gut fat depots in a diet-induced dysbiosis animal model.Methods: Male Wistar rats were fed either a standard diet (control, n=10) or a high-fat high-sucrose diet (HFSD, n=10) for 14 weeks. Measurements included serum glucose, lipid-lipoprotein profile, free fatty acids (FFAs), lipopolysaccharide (LPS) and the Firmicutes/Bacteroidetes (F/B) ratio in stool samples, via real-time quantitative polymerase chain reaction. Lipid content in isolated CMs (ultracentrifugation d <0.95 g/mL) was assessed, and MTTP, cell intestinal fat content (CIF), histology, apoB mRNA and tight junction (TJ) proteins were analyzed, in intestinal tissue.Results: Compared to control, HFSD rats showed higher levels of LPS, triglycerides (TGs), non-high-density lipoprotein cholesterol (HDL-C) levels, TG/HDL-C ratio, FFAs, and the F/B ratio. HFSD CMs showed increased TG and phospholipids. TJ proteins levels were lower in the HFSD group, while histological scores showed no differences. CIF was increased in the HFSD group. No significant differences in apoB mRNA were found. MTTP expression was higher in the HFSD group, and directly correlated with CM-TG and inversely correlated with CIF.Conclusion: Our findings imply that gut TG content may constitute an important determinant of the secretion of TG-rich CMs, promoted by MTTP, with increased atherogenic potential.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"14 1","pages":"106-119"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Journal of Lipid and Atherosclerosis in 2025: From Excellence to Eminence.

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2025-01-18 DOI: 10.12997/jla.2025.14.1.1

In-Kyung Jeong

引用次数: 0

Application of Generative Artificial Intelligence in Dyslipidemia Care.

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2024-12-10 DOI: 10.12997/jla.2025.14.1.77

Jihyun Ahn, Bokyoung Kim

{"title":"Application of Generative Artificial Intelligence in Dyslipidemia Care.","authors":"Jihyun Ahn, Bokyoung Kim","doi":"10.12997/jla.2025.14.1.77","DOIUrl":"10.12997/jla.2025.14.1.77","url":null,"abstract":"Dyslipidemia dramatically increases the risk of cardiovascular diseases, necessitating appropriate treatment techniques. Generative AI (GenAI), an advanced AI technology that can generate diverse content by learning from vast datasets, provides promising new opportunities to address this challenge. GenAI-powered frequently asked questions systems and chatbots offer continuous, personalized support by addressing lifestyle modifications and medication adherence, which is crucial for patients with dyslipidemia. These tools also help to promote health literacy by making information more accessible and reliable. GenAI helps healthcare providers construct clinical case scenarios, training materials, and evaluation tools, which supports professional development and evidence-based practice. Multimodal GenAI technology analyzes food images and nutritional content to deliver personalized dietary recommendations tailored to each patient's condition, improving long-term nutritional management for those with dyslipidemia. Moreover, using GenAI for image generation enhances the visual quality of educational materials for both patients and professionals, allowing healthcare providers to create real-time, customized visual aids. To apply successfully, healthcare providers must develop GenAI-related abilities, such as prompt engineering and critical evaluation of GenAI-generated data.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"14 1","pages":"77-93"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791424/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atherosclerotic Cardiovascular Disease in Cancer Survivors: Current Evidence, Risk Prediction, Prevention, and Management.

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2024-07-19 DOI: 10.12997/jla.2025.14.1.30

Arum Choi, Subin Kim, Seonji Kim, Iksung Cho, Min Jae Cha, Seng Chan You

{"title":"Atherosclerotic Cardiovascular Disease in Cancer Survivors: Current Evidence, Risk Prediction, Prevention, and Management.","authors":"Arum Choi, Subin Kim, Seonji Kim, Iksung Cho, Min Jae Cha, Seng Chan You","doi":"10.12997/jla.2025.14.1.30","DOIUrl":"10.12997/jla.2025.14.1.30","url":null,"abstract":"While advances in cancer treatment have led to improved survival rates, cancer survivors are at a significant risk of developing atherosclerotic cardiovascular disease (ASCVD). This review examines the risk, diagnosis, and prevention of ASCVD in this population. Cancer survivors, especially those diagnosed with certain types, face a significantly higher risk of developing ASCVD than the general population. We introduce the \"triad model\" to explain this increased risk of ASCVD among cancer patients. This model includes three interconnected components: common catalysts, cancer influence, and treatment impact. The factors contributing to this model are the shared risk factors between cancer and ASCVD, such as smoking, obesity, and systemic inflammation; the direct effects of cancer on cardiovascular health through chronic systemic inflammation and endothelial damage; and the significant effects of anticancer treatments, including chemotherapy and radiation, which can worsen cardiovascular complications and hasten the progression of ASCVD. Furthermore, cancer survivors are at a higher risk of developing and dying from ASCVD, highlighting the necessity for tailored guidelines and strategies for ASCVD prevention and management in this population. The review explores the utility of diagnostic tools, such as coronary artery calcium scoring, in predicting and managing ASCVD risk. It also emphasizes the importance of prevention strategies that include regular cardiovascular monitoring and lifestyle modifications. Finally, the relationship between cancer survival and cardiovascular health highlights the importance of integrated and comprehensive care approaches. Continued research, the development of prediction models, and specific preventative strategies are essential to improve cancer survivors' overall health outcomes.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"14 1","pages":"30-39"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Discrepant Effect of High-Density Lipoprotein Cholesterol on the Hematologic Malignancy Risk: A Nationwide Cohort Study.

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2024-10-28 DOI: 10.12997/jla.2025.14.1.94

Su Youn Nam, Junwoo Jo, Won Kee Lee

{"title":"Discrepant Effect of High-Density Lipoprotein Cholesterol on the Hematologic Malignancy Risk: A Nationwide Cohort Study.","authors":"Su Youn Nam, Junwoo Jo, Won Kee Lee","doi":"10.12997/jla.2025.14.1.94","DOIUrl":"10.12997/jla.2025.14.1.94","url":null,"abstract":"Objective: Although high-density lipoprotein cholesterol (HDL-C) is inversely associated with hematologic malignancies, modification by smoking has not been reported. We investigated how smoking and menopausal status modify these association.Methods: This population-based cohort study enrolled cancer-free individuals who underwent a national cancer screening in 2010 and followed up until December 2017. HDL-C levels were classified into eight groups based on 10 mg/dL intervals: (<30, 30-39, 40-49, 50-59, 60-69, 70-79, 80-89, or ≥90 mg/dL).Results: Among 4,517,892 participants, 5887 had lymphoma, 3348 had leukemia, and 12151 had unspecified hematologic malignancies. The adjusted hazard ratios (aHRs) for the lowest HDL-C levels compared to the 70-79 mg/dL range were 1.83 (1.45-2.31) for lymphoma, 3.14 (2.41-4.08) for leukemia, and 2.34 (2.01-2.72) for unspecified hematologic malignancy. The effects of low HDL-C levels on hematologic malignancies were similar in both men and women. Low HDL-C levels were associated with a higher risk of leukemia regardless of smoking status, but extremely high HDL-C levels were linked to a higher risk of leukemia (aHR, 2.32; 95% confidence interval [95% CI], 1.18-4.55) only in current smokers.The hazardous effect of low HDL-C levels on lymphoma was significant only in never smokers (aHR, 2.01; 95% CI, 1.51-2.68). Hazardous effects of low HDL-C levels on leukemia were observed only in post-menopausal women (aHR, 2.94; 95% CI, 1.69-5.11).Conclusion: Low HDL-C levels were associated with a higher risk of leukemia and lymphoma, with discrepancies based on smoking and menopausal status.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"14 1","pages":"94-105"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular Pathways in Diabetic Cardiomyopathy and the Role of Anti-hyperglycemic Drugs Beyond Their Glucose Lowering Effect.

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2024-11-28 DOI: 10.12997/jla.2025.14.1.54

Jie-Eun Lee, Byung Gyu Kim, Jong Chul Won

引用次数: 0

Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2024-06-26 DOI: 10.12997/jla.2025.14.1.5

Fernando Bril, Gabriela Berg, Magali Barchuk, Juan Patricio Nogueira

{"title":"Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.","authors":"Fernando Bril, Gabriela Berg, Magali Barchuk, Juan Patricio Nogueira","doi":"10.12997/jla.2025.14.1.5","DOIUrl":"10.12997/jla.2025.14.1.5","url":null,"abstract":"Dyslipidemia is a major risk factor for cardiovascular disease, and its impact may be exacerbated when accompanied by metabolic dysfunction-associated steatotic liver disease (MASLD). The simultaneous management of these conditions poses multiple challenges for healthcare providers. Insulin resistance has been implicated in the pathogenesis of both dyslipidemia and MASLD, necessitating a holistic approach to managing dyslipidemia, glucose levels, body weight, and MASLD. This review explores the intricate pathophysiological relationship between MASLD and dyslipidemia. It also examines current guidance regarding the use of lipid-lowering agents (including statins, ezetimibe, fibrates, omega-3 polyunsaturated fatty acids, and proprotein convertase subtilisin/kexin type 9 inhibitors) as well as glucose-lowering medications (such as pioglitazone, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter 2 inhibitors) in patients with MASLD, with or without metabolic dysfunction-associated steatohepatitis (MASH), and dyslipidemia. Additionally, the review addresses the potential of emerging drugs to concurrently target both MASLD/MASH and dyslipidemia. Our hope is that a deeper understanding of the mechanisms underlying MASLD and dyslipidemia may assist clinicians in the management of these complex cases.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"14 1","pages":"5-29"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to Letter Regarding Article, Statins Ticagrelor and Rhabdomyolysis: A Coincidence or a Drug Interaction?

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2025-01-15 DOI: 10.12997/jla.2025.14.1.130

Jai Bharat Sharma, Ramesh Patel

引用次数: 0